ABSTRACT
BACKGROUND & AIMS: Most studies on autoimmune hepatitis (AIH) in children are in predominantly Caucasian cohorts. Paediatric AIH in African Americans (AA) is understudied, with a dearth of clinical predictors of outcome, often leading to serious complications and even mortality. The aim of the study was to define disease presentation, progression, response to therapy and outcomes in paediatric AIH in a well-defined, large, single centre, demographically diverse population. METHODS: We conducted a review of patients with AIH who were followed at this tertiary liver transplant centre. Clinical and laboratory covariates were assessed with regard to disease presentation, progression and outcomes in AA vs Non-AA children. RESULTS: African Americans patients constituted 42% of this cohort. At 1-year follow-up, AA children were receiving significantly higher doses of steroids compared to non-AA. More AA presented with end-stage liver disease (ESLD) with high immunoglobulin G and GGT:platelet ratio. After adjusting for other risk factor variables like gender, age at presentation and ESLD, AA children were at 4.5 times higher risk for significant outcome liver transplant/death within the first 12 months of presentation. Post-transplant, recurrent AIH was seen in 50% of AA vs 8% in non-AA. CONCLUSIONS: African American patients with AIH are more likely to present with ESLD and have an increased early risk for transplantation with high likelihood of disease recurrence post-transplantation. Studies are needed to delineate factors such as inherent biology, genetics and access to care. Early referral and tailored immunosuppressive regimens are required for AA patients with AIH.
Subject(s)
Black or African American/statistics & numerical data , End Stage Liver Disease/therapy , Health Status Disparities , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/etiology , Liver Transplantation/adverse effects , Adolescent , Child , Cohort Studies , Female , Georgia , Hepatitis, Autoimmune/diagnosis , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/mortality , Male , Recurrence , Risk FactorsABSTRACT
INTRODUCTION & AIMS: Small studies have found that black patients with autoimmune hepatitis (AIH) present with more aggressive disease. We aimed to characterize the presentation and outcome in black and white patients with AIH. METHODS: We performed a retrospective study, collecting information from databases of patients with AIH attending the Institute of Liver studies at King's College Hospital, London (1971-October 2015, the Royal Free Hospital, London (1982 through December 2016) and the multicenter Dutch Autoimmune Hepatitis Study Group cohort (2006-August 2016). We identified 88 black patients with AIH and we compared their clinical characteristics and outcomes to 897 white patients with AIH. RESULTS: Black patients presented at a younger age (median 38 years vs 45 years) (P = .007), had higher IgG levels (mean 31.0 mg/dL vs 27.5 mg/dL) (P = .04), but there were no significant differences between groups in auto-antibody profiles, International AIH Group scores, or sex distribution of disease. A higher proportion of black patients had systemic lupus erythematosus (10%) than white patients (2%) (P ≤ .001). There was no significant difference in proportions of patients with a response to standard therapy (86% for black patients vs 91% for white patients; P = .20) or in rate of relapse (57% vs 50%; P = .3). Despite this, black patients had an increased risk of liver transplantation and liver-related death (hazard ratio 2.4, 95% confidence interval, 1.4-4.0; P < .001). Overall mortality was similar between the two groups. CONCLUSION: In a comparison of black and white patients with AIH in Europe, we found that black patients present at a younger age, have higher levels of IgG levels, and a greater proportion have SLE. We also found black patients to have a greater risk of liver transplantation and liver-related mortality, indicating more aggressive disease.
Subject(s)
Black People , Hepatitis, Autoimmune/ethnology , Liver Transplantation , Prednisolone/therapeutic use , Adult , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , Hepatitis, Autoimmune/therapy , Humans , Incidence , Male , Middle Aged , Prognosis , Retrospective Studies , United Kingdom/epidemiologyABSTRACT
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease characterized by an autoimmune reaction to hepatocytes. A single nucleotide polymorphism in the 3' untranslated region of HLA-DPB1, rs9277534, is associated with HLA-DPB1 expression. rs9277534 has been linked to hepatitis B virus recovery/persistence and the risk of graft-versus-host disease with HLA-DPB1 mismatching transplantation of hematopoietic cells, but its role along with that of HLA-DP expression in AIH have not been fully clarified. We genotyped rs9277534 in 146 Japanese patients with AIH and 326 healthy subjects. HLA-DPB1 expression was determined by quantitative PCR. HLA-DPB1 expression was significantly higher for rs9277534G than for rs9277534A (P < 0.05). rs9277534 genotype was in strong linkage disequilibrium with the HLA-DPB1 allele (pairwise D' = 0.82-1.00). Although HLA-DP alleles were not significantly associated with AIH, the frequency of the rs9277534G allele was significantly higher in AIH patients compared with healthy subjects (P = 0.002, odds ratio [OR] = 1.56). Logistic regression analysis revealed that the HLA-DRB1*04:05 allele (P < 0.001, OR = 4.61) and rs9277534 (P = 0.004, OR = 1.67) were independently associated with AIH susceptibility. rs9277534G in the HLA-DP gene is an eQTL that affects gene expression and may contribute to AIH susceptibility.
Subject(s)
Genetic Predisposition to Disease/genetics , HLA-DP beta-Chains/genetics , Hepatitis, Autoimmune/genetics , Polymorphism, Single Nucleotide , Quantitative Trait Loci , 3' Untranslated Regions/genetics , Aged , Alleles , Asian People/genetics , Female , Gene Frequency , Genetic Predisposition to Disease/ethnology , Genotype , Hepatitis, Autoimmune/classification , Hepatitis, Autoimmune/ethnology , Humans , Japan , Male , Middle AgedABSTRACT
Several studies reported that autoimmune diseases share a number of susceptibility genes. Of these genes, a SNP rs7708392 in TNIP1 was reported to be associated with systemic lupus erythematosus (SLE). Autoimmune hepatitis (AIH), a rare chronic progressive liver disease, shares some clinical features with SLE. Therefore, we investigated whether the SNP is associated with Japanese AIH. An association study of rs7708392 was conducted in 343 Japanese AIH patients and 828 controls. We found that rs7708392 is associated with AIH (P = 0.0236, odds ratio (OR) 1.26, 95% confidence interval (CI): 1.03-1.54), under the allele model for C allele. Significant differences of clinical characteristics of the AIH patients with or without G allele of rs7708392 were not detected. Of interest, the association was stronger in AIH without HLA-DRB1*04:05 allele (P = 0.0063, Q = 0.0127, OR 1.48, 95% CI: 1.12-1.96), though the association was not detected in AIH with DRB1*04:05. The C allele of rs7708392 was associated with AIH, especially AIH without DRB1*04:05, an already established risk factor.
Subject(s)
DNA-Binding Proteins/genetics , Genetic Predisposition to Disease , Hepatitis, Autoimmune/genetics , Polymorphism, Single Nucleotide , Adult , Aged , Asian People/genetics , Case-Control Studies , Female , Gene Frequency , HLA-DRB1 Chains/genetics , Hepatitis, Autoimmune/ethnology , Humans , Japan , Male , Middle Aged , Real-Time Polymerase Chain ReactionABSTRACT
OBJECTIVES: The healthcare burden of autoimmune hepatitis (AIH) in the United States has not been characterized. We previously showed that AIH disproportionately affects people of color in a single hospital system. The current study aimed to determine whether the same disparity occurs nationwide. METHODS: We analyzed hospitalizations with a primary discharge diagnosis corresponding to the ICD-9 code for AIH in the National Inpatient Sample between 2008 and 2012. For each racial/ethnic group, we calculated the AIH hospitalization rate per 100,000 population and per 100,000 all-cause hospitalizations, then calculated a risk ratio compared to the reference rate among whites. We used multivariable logistic regression models to assess for racial disparities and to identify predictors of in-hospital mortality during AIH hospitalizations. RESULTS: The national rate of AIH hospitalization was 0.73 hospitalizations per 100,000 population. Blacks and Latinos were hospitalized for AIH at a rate 69% (P<0.001) and 20% higher (P<0.001) than whites, respectively. After controlling for age, gender, payer, residence, zip code income, region, and cirrhosis, black race was a statistically significant predictor for mortality during AIH hospitalizations (odds ratio (OR) 2.81, 95% confidence interval (CI) 1.43, 5.47). CONCLUSIONS: Hospitalizations for AIH disproportionately affect black and Latino Americans. Black race is independently associated with higher odds of death during hospitalizations for AIH. This racial disparity may be related to biological, genetic, environmental, socioeconomic, and healthcare access and quality factors.
Subject(s)
Black or African American/statistics & numerical data , Hepatitis, Autoimmune/ethnology , Hispanic or Latino/statistics & numerical data , Hospital Mortality/ethnology , Hospitalization/statistics & numerical data , Adult , Ascites/ethnology , Ascites/etiology , Female , Hepatic Encephalopathy/ethnology , Hepatic Encephalopathy/etiology , Hepatitis, Autoimmune/complications , Hepatitis, Autoimmune/mortality , Hepatitis, Autoimmune/therapy , Humans , Male , Middle Aged , United States/epidemiology , White People/statistics & numerical data , Young AdultABSTRACT
RESUMO A insuficiência hepática aguda é uma síndrome rara com elevada mortalidade e frequentemente reconhecida de forma tardia. Os médicos intensivistas desempenham um papel fundamental na suspeição diagnóstica e no manejo das disfunções múltiplo-orgânicas características desta entidade. A síndrome inflamatória de reconstituição imune é uma entidade que se caracteriza pela piora paradoxal do quadro prévio do paciente, após o início de antirretrovirais, desencadeada contra patógenos presentes no hospedeiro ou autoantígenos. A hepatite autoimune tem sido recentemente descrita como uma destas manifestações autoimunes. Os autores relatam o primeiro caso com evolução à insuficiência hepática aguda e óbito em poucos dias após o desenvolvimento de encefalopatia, revisam os casos de hepatite autoimune descritos e tecem comentários sobre as possibilidades terapêuticas neste contexto.
ABSTRACT Acute liver failure is a rare syndrome with high mortality and is often diagnosed late. Intensivist physicians play fundamental roles in the diagnostic suspicion and the management of the multiple-organic dysfunctions characteristic of this entity. Immune reconstitution inflammatory syndrome is an entity that is characterized by the paradoxical worsening of the patient's previous condition, after the initiation of antiretrovirals, triggered against either pathogens present in the host or autoantigens. Autoimmune hepatitis has recently been described as one of these autoimmune manifestations. The authors report the first case with evolution to acute liver failure and death within a few days after the development of encephalopathy, review the cases of autoimmune hepatitis described and comment on the therapeutic possibilities in this context.
Subject(s)
Humans , Female , Liver Failure, Acute/etiology , Hepatitis, Autoimmune/ethnology , Immune Reconstitution Inflammatory Syndrome/complications , Liver Failure, Acute/diagnosis , Fatal Outcome , Hepatitis, Autoimmune/diagnosis , Immune Reconstitution Inflammatory Syndrome/diagnosis , Middle AgedABSTRACT
BACKGROUND: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology. Increasing incidence of AIH in Asian patients has been reported. However, the phenotypic difference of Asian patients in Europe and Asia has still not been explored. AIM: To evaluate the clinical presentation, biochemical and immunological profiles, treatment response and survival outcome of type 1 AIH from two tertiary liver transplant centres (United Kingdom and Singapore). METHOD: Patients who fulfilled the simplified diagnostic scoring criteria of AIH were included in the study. Patients with overlap syndrome were excluded. RESULTS: Totals of 40 Asian patients and 159 Caucasian patients from the University Hospital of Birmingham National Health Service Foundation Trust, UK, were compared with 57 Asian patients from Singapore General Hospital, Singapore. Asian patients from Singapore present significantly much later (median 55 vs. 32 years, p < 0.001), had higher MELD (p < 0.001) with lower albumin (p < 0.001) and higher bilirubin (p < 0.001) and lower ASMA positivity (p < 0.001) at diagnosis compared to UK Asian. Jaundice at presentation was much higher in Singapore Asian patients compared to UK Asian (53 vs. 30 %) but cirrhosis at diagnosis was more common in UK patients. Associated autoimmune conditions were less commonly seen in Singapore Asians. Comparing between UK cohorts, Asian patients present at younger age and have higher IgG level compared to Caucasian. Overall, 5-year transplant-free survival in all three cohorts was similar (p = 0.846). CONCLUSION: We demonstrate that AIH patients from Singapore present at older age with jaundice and have a low positivity of SMA. Despite these differences, transplant-free survival is similar in the two groups.
Subject(s)
Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/therapy , Adult , Female , Hepatitis, Autoimmune/immunology , Hepatitis, Autoimmune/pathology , Humans , Immunoglobulin G/immunology , Jaundice/ethnology , Jaundice/immunology , Jaundice/pathology , Jaundice/therapy , Liver Cirrhosis/ethnology , Liver Cirrhosis/immunology , Liver Cirrhosis/pathology , Liver Cirrhosis/therapy , Male , Middle Aged , Singapore , Survival Analysis , Treatment Outcome , United Kingdom , Young AdultABSTRACT
BACKGROUND/AIMS: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibodies are observed in autoimmune diseases, as well as in patients with autoimmune autonomic ganglionopathy. However, the genetic background of anti-gAChR antibodies is unclear. Here, we investigated HLA alleles in autoimmune hepatitis (AIH) patients with or without anti-gAChR antibodies. METHODOLOGY/PRINCIPAL FINDINGS: Genomic DNA from 260 patients with type-1 autoimmune hepatitis (AIH) were genotyped for HLA-A, B, DRB1, and DQB1 loci. Anti-gAChR antibodies in the sera form AIH patients were measured using the luciferase immunoprecipitation system, and examined allelic association in patients with or without anti-gAChR antibodies. METHODOLOGY/ METHODS: We detected anti-α3 or -ß4 gAChR antibodies in 11.5% (30/260) of patients with AIH. Among AIH patients there was no significant association between HLA-A, B DQB1 alleles and the positivity for anti-gAChR antibodies. Whereas the HLA-DRB1*0403 allele showed a significantly increased frequency in AIH patients with anti-gAChR antibodies compared with those without anti-gAChR antibodies. CONCLUSIONS/SIGNIFICANCE: The frequency of the HLA-DRB1*0403 allele differed among Japanese patients with AIH according to the presence or absence of anti-gAChR antibodies. Our findings suggest that particular HLA class II molecules might control the development of anti-gAChR antibodies in the autoimmune response to gAChR.
Subject(s)
Asian People/genetics , Autoantibodies/immunology , HLA-DRB1 Chains/genetics , Hepatitis, Autoimmune/genetics , Nerve Tissue Proteins/immunology , Receptors, Nicotinic/immunology , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Alleles , Autoimmune Diseases/epidemiology , Case-Control Studies , Comorbidity , Female , Follow-Up Studies , Gene Frequency , Genes, MHC Class I , Genes, MHC Class II , Genetic Predisposition to Disease , Genotype , HLA Antigens/genetics , HLA-D Antigens/genetics , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/immunology , Humans , Japan , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Previous genome-wide association studies have evaluated the impact of common genetic variants and identified several non-HLA risk loci associated with autoimmune liver diseases. More recent genome-wide association studies and replication analyses reported an association between variants of the CARD10 polymorphism rs6000782 and risk of type 1 autoimmune hepatitis (AIH). In this case-control study, we genotyped 326 Japanese AIH patients and 214 control subjects. RESULTS: Genomic DNA from 540 individuals of Japanese origin, including 326 patients with type-1 AIH and 214 healthy controls, was analyzed for two single nucleotide polymorphisms (SNPs) in the CARD10 gene. We selected CARD10 rs6000782 SNPs and genotyped these using PCR-RFLP method and direct sequencing. The Chi square test revealed that the rs6000782 variant alle (c) was not associated with the susceptibility for AIH in a Japanese population [p = 0.376, odds ratio (OR) 1.271, 95 % confidence interval (CI) 0.747-2.161] in an allele model. Our data also showed that CARD10 rs6000782 variants were not associated with AIH or with the clinical parameters of AIH. CONCLUSIONS: In this study we examined an association between rs6000782 SNPs in the CARD10 gene and type-1 AIH. Results showed no significant association of rs62000782 with type-1 AIH in a Japanese population. This study demonstrated no association between CARD10 rs6000782 variants and AIH in a Japanese population.
Subject(s)
CARD Signaling Adaptor Proteins/genetics , Genetic Predisposition to Disease/genetics , Hepatitis, Autoimmune/genetics , Polymorphism, Single Nucleotide , Aged , Asian People/genetics , Base Sequence , Case-Control Studies , Chi-Square Distribution , Female , Gene Frequency , Genetic Predisposition to Disease/ethnology , Genotype , Hepatitis, Autoimmune/classification , Hepatitis, Autoimmune/ethnology , Humans , Japan , Linkage Disequilibrium , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Risk Factors , Sequence Analysis, DNAABSTRACT
AIM: To investigate the prevalence of autoantibodies and their associations with clinical features in Chinese patients with chronic hepatitis B (CHB). METHODS: A total of 325 Chinese patients with CHB were enrolled in this retrospective, hospital-based study. Patients with chronic hepatitis C (CHC), autoimmune hepatitis (AIH), or primary biliary cirrhosis (PBC) were included, with healthy donors acting as controls. A panel of autoantibodies that serologically define AIH and PBC was tested by indirect immunofluorescence assay and line immunoassay. The AIH-related autoantibody profile included homogeneous anti-nuclear antibodies (ANA-H), smooth-muscle antibodies, anti-liver kidney microsome type 1, anti-liver cytosolic antigen type 1, and anti-soluble liver antigen/liver pancreas; the PBC-related antibodies were characterized by ANA-nuclear dots/membranous rim-like, anti-mitochondrial antibodies-M2 (AMA-M2), anti-BPO (recombinant antigen targeted by AMA-M2), anti-Sp100, anti-promyelocytic leukemia protein (anti-PML), and anti-gp210. The dichotomization of clustering was used to unequivocally designate the AIH or PBC profiles for each case. Anti-Ro52 antibodies were also tested. RESULTS: The prevalence of any autoantibody in CHB amounted to 58.2%, which was similar to the 66.2% prevalence in CHC, significantly higher than the 6.7% in the healthy controls (P < 0.001), and lower than the 100% found in AIH and PBC (P = 0.004 and P < 0.001, respectively). There were more anti-PML and anti-gp210 antibodies among the CHB patients than the CHC patients (11.1% vs 0%, P = 0.003; 12.6% vs 0%, P < 0.001, respectively). The prevalence and titer of AMA, anti-BPO, anti-PML, and anti-gp210 were higher in PBC than in those with CHB. Among the CHB patients, the prevalence of ANA, especially ANA-H, was significantly lower in patients with compensated and decompensated cirrhosis compared with patients without cirrhosis. Thirty-eight cases of hepatocellular carcinoma (HCC) in CHB showed a significant difference compared with non-HCC patients in the prevalence of anti-PML (0% vs 12.5%, P = 0.013). Dichotomization of the autoantibodies revealed that the PBC profile was more prevalent in patients with CHB than in those with CHC, and that it was strongly correlated with both compensated and decompensated cirrhosis. In contrast, the prevalence of the AIH profile was significantly higher in non-cirrhosis patients with CHB than in those with compensated cirrhosis (18.5% vs 8.2%, P = 0.039). Moreover, the AIH profile was also closely associated with hepatitis B e-antigen positivity. CONCLUSION: ANA-H could be an indicator of early-stage CHB. Dichotomizing the autoantibody profiles revealed that the PBC profile is strongly associated with cirrhosis in CHB.
Subject(s)
Asian People , Autoantibodies/blood , Hepatitis B, Chronic/ethnology , Hepatitis B, Chronic/immunology , Adult , Biomarkers/blood , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/ethnology , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/virology , China/epidemiology , Diagnosis, Differential , Female , Hepatitis B e Antigens/blood , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/diagnosis , Hepatitis, Autoimmune/blood , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/immunology , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/ethnology , Liver Cirrhosis/immunology , Liver Cirrhosis/virology , Liver Cirrhosis, Biliary/blood , Liver Cirrhosis, Biliary/ethnology , Liver Cirrhosis, Biliary/immunology , Liver Neoplasms/blood , Liver Neoplasms/ethnology , Liver Neoplasms/immunology , Liver Neoplasms/virology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Retrospective Studies , Seroepidemiologic StudiesABSTRACT
Autoimmune hepatitis has diverse clinical phenotypes and outcomes in ethnic groups within a country and between countries, and these differences may reflect genetic predispositions, indigenous etiological agents, pharmacogenomic mechanisms and socioeconomic reasons. In the USA, African-American patients have cirrhosis more commonly, treatment failure more frequently and higher mortality than white American patients. Survival is poorest in Asian-American patients. Autoimmune hepatitis in other countries is frequently associated with genetic predispositions that may favor susceptibility to indigenous etiological agents. Cholestatic features influence treatment response; acute-on-chronic liver disease increases mortality and socioeconomic and cultural factors affect prognosis. Ethnic-based deviations from classical phenotypes and the frequency of late-stage disease can complicate the diagnosis and management of autoimmune hepatitis in non-white populations.
Subject(s)
Ethnicity , Hepatitis, Autoimmune/ethnology , Racial Groups , Residence Characteristics , Ethnicity/genetics , Genetic Predisposition to Disease , Health Status Disparities , Healthcare Disparities/ethnology , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/mortality , Hepatitis, Autoimmune/therapy , Humans , Phenotype , Prognosis , Racial Groups/genetics , Risk Factors , Socioeconomic FactorsABSTRACT
BACKGROUND AND AIMS: Disease recurrence following transplantation occurs in 20-45% of patients with autoimmune hepatitis (AIH). Factors associated with an increased risk of recurrence include human leukocyte antigen (HLA) DR3 and HLA DR4 positivity, inadequate immunosuppression, and severity of inflammation in the native liver. Titers of several autoantibodies can be elevated in patients with AIH, including antinuclear antibody (ANA) and antismooth muscle antibody (SMA); however, it is unclear whether or not the degree of elevation influences the risk of disease recurrence following transplantation. METHODS: We conducted a retrospective study to evaluate the potential impact of pretransplant titers on post-transplant outcomes for patients with AIH. Sixty-three patients with AIH who underwent 72 liver transplants between 1 January 1989 and 1 January 2009 were included, with a median follow up of 10 months. Patients were divided into group A (ANA or SMA ≥ 1:160) and group B (titers ≤ 1:160). RESULTS: There was no significant difference in the recurrence rates or death between patients in groups A and B, respectively. Only race appeared to impact outcomes, with African American patients having a higher incidence of death and recurrent disease post-transplant compared to other ethnicities. CONCLUSIONS: Based on our findings, pretransplant ANA and SMA levels do not appear to impact recurrence rates or outcomes following liver transplantation for AIH.
Subject(s)
Autoantibodies/blood , Graft Survival/immunology , Hepatitis, Autoimmune/surgery , Liver Transplantation/immunology , Adult , Black or African American , Antibodies, Antinuclear/blood , Biomarkers/blood , Female , Fluorescent Antibody Technique, Indirect , Follow-Up Studies , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/immunology , Hepatitis, Autoimmune/mortality , Humans , Logistic Models , Male , Middle Aged , Preoperative Period , Recurrence , Retrospective Studies , Survival Analysis , Treatment OutcomeABSTRACT
UNLABELLED: The long-term outcome of patients with autoimmune hepatitis (AIH) in Japan has not been well-defined. The aim of this study was to clarify the outcome of this disease over a long follow-up period compared with that of the general Japanese population as well as that among patients. A total of 203 AIH patients were enrolled for a mean follow-up period of 131 months. All patients were treated with corticosteroids with or without azathioprine. The overall survival of AIH patients was similar to that of the general population in Japan. The prognosis of AIH subgroups divided according to disease severity, sex, incidence of relapse, liver histology, presence of cirrhosis, probable or definite AIH score, antibody to hepatitis B core antigen antibody positivity, or human leukocyte antigen DR4-positivity did not differ greatly among patients. However, the prognosis of patients experiencing two or more relapses was significantly poorer than that of patients with remission or a single relapse both in univariate (P < 0.001) and multivariate (P = 0.020) analyses. The development of liver malignancy was also a possibility among AIH patients with multiple relapses. Severe adverse effects of corticosteroids were rare, even in patients who underwent long-term treatment. CONCLUSION: Repeated relapses of AIH are significantly associated with a poorer long-term prognosis in Japan. AIH patients can expect a similar prognosis to that of the general population, provided they are adequately managed with continuous low doses of immunosuppressive therapy, especially after the first relapse.
Subject(s)
Asian People/statistics & numerical data , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/mortality , Cerebral Hemorrhage/mortality , Child , Female , Follow-Up Studies , Glucocorticoids/administration & dosage , Hepatitis, Autoimmune/drug therapy , Humans , Japan/epidemiology , Liver Failure/mortality , Liver Neoplasms/mortality , Male , Middle Aged , Prednisolone/administration & dosage , Prospective Studies , Recurrence , Young AdultABSTRACT
UNLABELLED: : BACKGROUND: Up to now, few data are available regarding the clinical characteristics of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. The study was to investigate and analyze the prevalent and clinical features of Chinese patients with this disease. METHODS: Clinical data on patients diagnosed as autoimmune hepatitis and primary biliary cirrhosis overlap syndrome in our hospital from January 2001 to December 2006 were collected and analyzed. RESULTS: Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis accounted for 10.33% of patients with autoimmune liver diseases during the past six years. For these patients with overlap syndrome, xanthochromia, lethargy and anorexia were the predominant complaints; a low incidence (14/146) of smooth muscle antibody positivity and a high incidence (37/89) of isolated IgM elevation were the main serological characteristics. CONCLUSIONS: Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis was not rare in Chinese patients with clinical manifests of autoimmune liver diseases. Overlap of the diseases should not be disregarded when isolated IgM elevation was exhibited, and smooth muscle antibody might have little diagnostic significance in the overlap syndrome. If it was difficult to make a definite diagnosis, liver biopsy was necessary.
Subject(s)
Autoantibodies/blood , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/immunology , Immunoglobulin M/blood , Liver Cirrhosis, Biliary/ethnology , Liver Cirrhosis, Biliary/immunology , Muscle, Smooth/immunology , Adult , Antibodies, Antinuclear/blood , Biopsy , China , Female , Hepatitis, Autoimmune/blood , Humans , Liver/pathology , Liver Cirrhosis, Biliary/blood , Male , Middle Aged , Mitochondria/immunology , Retrospective Studies , SyndromeABSTRACT
GOALS: To evaluate race/ethnicity-specific variations in autoimmune hepatitis (AIH) with a focus on Asians and Hispanics, the fastest growing populations in the United States. BACKGROUND: AIH is a chronic inflammatory disease in which race/ethnicity-specific variations in clinical epidemiology have been reported. However, earlier studies were small or did not include a comprehensive analysis of Asians and Hispanics, the 2 fastest growing population cohorts in the United States. STUDY: A retrospective study analyzing patient data from 1999 to 2010 in a large tertiary-care community hospital to assess AIH epidemiology among a racially diverse population. RESULTS: One hundred eighty-three patients with AIH were included in the study with 81 patients having "definite" AIH by International Autoimmune Hepatitis Group criteria and 63 were diagnosed with overlap syndromes. Women and whites were the largest cohorts. The average age of diagnosis was similar among all groups. Biopsy-confirmed cirrhosis was present in 34% of AIH patients with Hispanics demonstrating the highest prevalence of cirrhosis (55%). When compared with whites, Asians had higher international normalized ratio (INR) (1.4 U vs. 1.1 U, P<0.01), and Hispanics had lower serum albumin (3.3 g/dL vs. 3.7 g/dL, P<0.001) and platelets (123.8 thousand/mcL vs. 187.5 thousand/mcL, P<0.001) and higher international normalized ratio (1.5 U vs. 1.1 U, P=0.05). Kaplan-Meier survival analysis demonstrated a trend toward worse outcomes among Asians. CONCLUSIONS: Among AIH patients, Hispanics had the highest prevalence of cirrhosis, and Asians had poorer survival outcomes. Race/ethnicity-specific disparities in AIH epidemiology may reflect underlying genetic differences, contributing to variations in disease severity, response to therapy, and overall mortality.
Subject(s)
Health Status Disparities , Healthcare Disparities , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/epidemiology , Liver Cirrhosis/ethnology , Liver Cirrhosis/epidemiology , Adult , Asian/genetics , Asian/statistics & numerical data , Chronic Disease , Ethnicity , Female , Healthcare Disparities/ethnology , Hepatitis, Autoimmune/physiopathology , Hispanic or Latino/statistics & numerical data , Humans , Liver Cirrhosis/physiopathology , Male , Middle Aged , Prevalence , Survival Analysis , United States/epidemiology , White People/genetics , White People/statistics & numerical dataABSTRACT
Autoimmune hepatitis has diverse clinical phenotypes that challenge conventional diagnostic criteria and treatment strategies. The goals of this review are to characterize these special populations and provide guidelines for their management. Patients with acute or acute severe (fulminant) presentations may have centrilobular zone 3 hepatic necrosis, but they can respond to conventional corticosteroid therapy. Asymptomatic mild disease warrants corticosteroid treatment because spontaneous resolution is uncertain and 10-year survival is less than expected. Male gender or the absence of conventional autoantibodies does not preclude the diagnosis or need for treatment, and patients with cholestatic changes warrant cholangiography and possible combination therapy with ursodeoxycholic acid. Different ethnic groups commonly have advanced hepatic fibrosis, rapidly progressive disease, or cholestatic features, and elderly patients typically respond well to corticosteroid therapy. Pregnancy is usually well-tolerated by mother and foetus but requires protection against postpartum exacerbation. Special populations must be recognized and treated with tailored regimens.
Subject(s)
Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/drug therapy , Pregnancy Complications/drug therapy , Racial Groups , Acute Disease , Aged , Aged, 80 and over , Asymptomatic Diseases , Autoantibodies/blood , Cholangitis, Sclerosing/complications , Cholestasis/etiology , Female , Hepatitis, Autoimmune/complications , Hepatitis, Autoimmune/ethnology , Humans , Liver Cirrhosis, Biliary/complications , Male , PregnancyABSTRACT
BACKGROUND: A higher incidence of autoimmune disorders may predispose First Nations (FN) individuals to higher rates and more severe episodes of rejection, graft loss and mortality following liver transplantation for advanced liver disease. METHODS: A retrospective review of patient outcomes in a single centre providing long-term follow-up care for FN and non-FN patients transplanted for advanced liver disease was conducted. RESULTS: A total of 20 FN and 129 non-FN charts were available for review. FN subjects were younger at transplantation (mean [± SD] age 32.4±4.1 years versus 46.3±1.4 years; P=0.00005), less often male (35% versus 58%; P=0.05), more commonly transplanted for autoimmune hepatitis (30% versus 4.7%; P=0.006), less often from urban residences (25% versus 74%; P=0.0001) and less compliant with medical care (20% versus 80%; P=0.007). After a mean follow-up period of 11.0±1.5 years and 8.4±0.5 years in FN and non-FN subjects, respectively, the incidence and severity of rejection, graft and patient survival were similar between cohorts. CONCLUSION: Although demographic profiles, nature of the underlying disease and compliance differed, the rates and severity of rejection, graft and patient survival were similar in FN and non-FN patients who underwent liver transplantation for advanced liver disease.
Subject(s)
Biliary Tract Diseases/ethnology , Biliary Tract Diseases/surgery , Graft Rejection/ethnology , Hepatitis, Autoimmune/ethnology , Hepatitis, Autoimmune/surgery , Liver Transplantation , Adult , Biliary Tract Diseases/pathology , Biliary Tract Diseases/physiopathology , Canada/epidemiology , Female , Graft Rejection/drug therapy , Graft Survival/drug effects , Hepatitis, Autoimmune/pathology , Hepatitis, Autoimmune/physiopathology , Humans , Immunosuppressive Agents/therapeutic use , Indians, North American , Liver/pathology , Liver/surgery , Liver Function Tests , Liver Transplantation/adverse effects , Liver Transplantation/ethnology , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Survival Analysis , Treatment OutcomeABSTRACT
AIM: To identify soluble liver antigen (SLA)-specific dominant epitopes and analyse the correlation between SLA-specific T cell response and the status of the disease. METHODS: A cross-sectional analysis of SLA-specific T cell responses to 54 overlapping peptides covering the entire SLA sequence was performed using an interferon (IFN)-γ ELISpot assay in 31 patients with auto-immune hepatitis (AIH)-1, 15 patients with primary biliary cirrhosis, 16 hepatitis B virus, seven hepatitis C virus infection and 10 healthy subjects, in order to assess the correlation between SLA-specific T cell responses and the clinical outcome. RESULTS: Soluble liver antigen-specific IFN-γ responses in AIH were significantly more frequent in AIH patients (58.1%) than those in controls (6.7% in PBC, P=0.001; 4.3% in hepatitis B/C, P<0.001 and 0% in healthy subjects, P=0.0015). Among 31 AIH patients, the frequency of recognition and the magnitude of response to SLA peptides in anti-SLA antibody-positive patients were higher and stronger than those negative for anti-SLA antibodies (P=0.02 and 0.037 respectively). We further analysed T-cell restriction and found that six individual SLA peptides (4, 9, 11, 12, 41 and 44) were recognized by CD4 T cells, and the most frequently recognized peptides were peptides 12 (61.1% of participants), followed by peptide 4 and peptide 44 (55.6 and 38.9% respectively). Moreover, a positive association was found between the breadth of recognition of SLA peptides and the indices of liver damage. CONCLUSION: T cell response to SLA in Chinese patients with AIH is broad and associated with hepatocyte damage.